Metabolomics and EMT Markers of Breast Cancer: A Crosstalk and Future Perspective

Overview

Journal Pathophysiology

Publisher MDPI

Specialty Pathology

Date 2022 Jun 23

PMID 35736645

Authors

Ajay Kumar Pal

Prateek Sharma

Alishan Zia

Deepali Siwan

Dipali Nandave

Mukesh Nandave

Rupesh K Gautam

Affiliations

Soon will be listed here.

Abstract

Cancer cells undergo transient EMT and MET phenomena or vice versa, along with the parallel interplay of various markers, often correlated as the determining factor in decoding metabolic profiling of breast cancers. Moreover, various cancer signaling pathways and metabolic changes occurring in breast cancer cells modulate the expression of such markers to varying extents. The existing research completed so far considers the expression of such markers as determinants regulating the invasiveness and survival of breast cancer cells. Therefore, this manuscript is crosstalk among the expression levels of such markers and their correlation in regulating the aggressiveness and invasiveness of breast cancer. We also attempted to cover the possible EMT-based metabolic targets to retard migration and invasion of breast cancer.

Citing Articles

Metabolic Profiling of Breast Cancer Cell Lines: Unique and Shared Metabolites.

Gallo M, Ferrari E, Brugnoli F, Terrazzan A, Ancona P, Volinia S Int J Mol Sci. 2025; 26(3).

PMID: 39940737 PMC: 11816582. DOI: 10.3390/ijms26030969.

Implications of Mineralization Biomarkers in Breast Cancer Outcomes Beyond Calcifications.

Giacobbi E, Bonfiglio R, Rotondaro G, Servadei F, Smirnov A, Palumbo V Int J Mol Sci. 2025; 26(2).

PMID: 39859358 PMC: 11765781. DOI: 10.3390/ijms26020645.

The impact of epithelial-mesenchymal transition (EMT) induced by metabolic processes and intracellular signaling pathways on chemo-resistance, metastasis, and recurrence in solid tumors.

Liaghat M, Ferdousmakan S, Mortazavi S, Yahyazadeh S, Irani A, Banihashemi S Cell Commun Signal. 2024; 22(1):575.

PMID: 39623377 PMC: 11610171. DOI: 10.1186/s12964-024-01957-4.

Mitochondrial inhibitors: a new horizon in breast cancer therapy.

Yan Y, Li S, Su L, Tang X, Chen X, Gu X Front Pharmacol. 2024; 15:1421905.

PMID: 39027328 PMC: 11254633. DOI: 10.3389/fphar.2024.1421905.

A new Neu-a syngeneic model of spontaneously metastatic HER2-positive breast cancer.

Baugh A, Gonzalez E, Narumi V, Kreger J, Liu Y, Rafie C Clin Exp Metastasis. 2024; 41(5):733-746.

PMID: 38717519 PMC: 11499368. DOI: 10.1007/s10585-024-10289-z.

References

Korpal M, Ell B, Buffa F, Ibrahim T, Blanco M, Celia-Terrassa T . Direct targeting of Sec23a by miR-200s influences cancer cell secretome and promotes metastatic colonization. Nat Med. 2011; 17(9):1101-8. PMC: 3169707. DOI: 10.1038/nm.2401. View

Sethi S, Sarkar F, Ahmed Q, Bandyopadhyay S, Nahleh Z, Semaan A . Molecular markers of epithelial-to-mesenchymal transition are associated with tumor aggressiveness in breast carcinoma. Transl Oncol. 2011; 4(4):222-6. PMC: 3140009. DOI: 10.1593/tlo.10244. View

Yang Y, Zhu G, Dong B, Piao J, Chen L, Lin Z . The NQO1/PKLR axis promotes lymph node metastasis and breast cancer progression by modulating glycolytic reprogramming. Cancer Lett. 2019; 453:170-183. DOI: 10.1016/j.canlet.2019.03.054. View

Choi Y, Chakrabarti R, Escamilla-Hernandez R, Sinha S . Elf5 conditional knockout mice reveal its role as a master regulator in mammary alveolar development: failure of Stat5 activation and functional differentiation in the absence of Elf5. Dev Biol. 2009; 329(2):227-41. DOI: 10.1016/j.ydbio.2009.02.032. View

Espinosa-Neira R, Mejia-Rangel J, Cortes-Reynosa P, Salazar E . Linoleic acid induces an EMT-like process in mammary epithelial cells MCF10A. Int J Biochem Cell Biol. 2011; 43(12):1782-91. DOI: 10.1016/j.biocel.2011.08.017. View

Xie L, Feng X, Huang M, Zhang K, Liu Q . Sonodynamic Therapy Combined to 2-Deoxyglucose Potentiate Cell Metastasis Inhibition of Breast Cancer. Ultrasound Med Biol. 2019; 45(11):2984-2992. DOI: 10.1016/j.ultrasmedbio.2019.07.008. View

Mani S, Guo W, Liao M, Eaton E, Ayyanan A, Zhou A . The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008; 133(4):704-15. PMC: 2728032. DOI: 10.1016/j.cell.2008.03.027. View

Timmerman L, Holton T, Yuneva M, Louie R, Padro M, Daemen A . Glutamine sensitivity analysis identifies the xCT antiporter as a common triple-negative breast tumor therapeutic target. Cancer Cell. 2013; 24(4):450-65. PMC: 3931310. DOI: 10.1016/j.ccr.2013.08.020. View

Zhu J, Thompson C . Metabolic regulation of cell growth and proliferation. Nat Rev Mol Cell Biol. 2019; 20(7):436-450. PMC: 6592760. DOI: 10.1038/s41580-019-0123-5. View

10.

Luo M, Brooks M, Wicha M . Asparagine and Glutamine: Co-conspirators Fueling Metastasis. Cell Metab. 2018; 27(5):947-949. DOI: 10.1016/j.cmet.2018.04.012. View

11.

Battula V, Shi Y, Evans K, Wang R, Spaeth E, Jacamo R . Ganglioside GD2 identifies breast cancer stem cells and promotes tumorigenesis. J Clin Invest. 2012; 122(6):2066-78. PMC: 3591166. DOI: 10.1172/JCI59735. View

12.

Hsu P, Sabatini D . Cancer cell metabolism: Warburg and beyond. Cell. 2008; 134(5):703-7. DOI: 10.1016/j.cell.2008.08.021. View

13.

Liu Y, Su P, Zhao W, Li X, Yang X, Fan J . ZNF213 negatively controls triple negative breast cancer progression via Hippo/YAP signaling. Cancer Sci. 2021; 112(7):2714-2727. PMC: 8253295. DOI: 10.1111/cas.14916. View

14.

Feng R, Morine Y, Ikemoto T, Imura S, Iwahashi S, Saito Y . Nrf2 activation drive macrophages polarization and cancer cell epithelial-mesenchymal transition during interaction. Cell Commun Signal. 2018; 16(1):54. PMC: 6122794. DOI: 10.1186/s12964-018-0262-x. View

15.

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

16.

Sotiriou C, Neo S, McShane L, Korn E, Long P, Jazaeri A . Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci U S A. 2003; 100(18):10393-8. PMC: 193572. DOI: 10.1073/pnas.1732912100. View

17.

Chakrabarti R, Hwang J, Blanco M, Wei Y, Lukacisin M, Romano R . Elf5 inhibits the epithelial-mesenchymal transition in mammary gland development and breast cancer metastasis by transcriptionally repressing Snail2. Nat Cell Biol. 2012; 14(11):1212-22. PMC: 3500637. DOI: 10.1038/ncb2607. View

18.

Li H, Huang J, Yang B, Xiang T, Yin X, Peng W . Mangiferin exerts antitumor activity in breast cancer cells by regulating matrix metalloproteinases, epithelial to mesenchymal transition, and β-catenin signaling pathway. Toxicol Appl Pharmacol. 2013; 272(1):180-90. DOI: 10.1016/j.taap.2013.05.011. View

19.

Mandal P, Freiter E, Bagsby A, Robertson F, McMurray J . Efficient synthesis of apricoxib, CS-706, a selective cyclooxygenase-2 inhibitor, and evaluation of inhibition of prostaglandin E2 production in inflammatory breast cancer cells. Bioorg Med Chem Lett. 2011; 21(20):6071-3. PMC: 3310163. DOI: 10.1016/j.bmcl.2011.08.050. View

20.

Shaul Y, Freinkman E, Comb W, Cantor J, Tam W, Thiru P . Dihydropyrimidine accumulation is required for the epithelial-mesenchymal transition. Cell. 2014; 158(5):1094-1109. PMC: 4250222. DOI: 10.1016/j.cell.2014.07.032. View